CHUQ Research Center/Hôpital Saint-François d'Assise, Québec City, Québec, Canada.
Clin Chem. 2010 Mar;56(3):361-75. doi: 10.1373/clinchem.2009.134080. Epub 2009 Dec 31.
Early identification of pregnant women at risk for preeclampsia is a priority to implement preventive measures. Some biochemical and ultrasonographic parameters have shown promising predictive performance, but so far there is no clinically validated screening procedure.
Using a series of keywords, we reviewed electronic databases (Medline, Embase, all records to May 2009) reporting the performance of biological and ultrasonographic markers to predict preeclampsia, both single markers and combinations of markers. We analyzed the data according to gestational age and risk levels of the studied populations. We evaluated the methodological quality of included publications using QUADAS (quality assessment of diagnostic accuracy studies). We identified 37 relevant studies that assessed 71 different combinations of biochemical and ultrasonographic markers. Most studies were performed during the second trimester on small-scale high-risk populations with few cases of preeclampsia. Combinations of markers generally led to an increase in sensitivity and/or specificity compared with single markers. In low-risk populations, combinations including placental protein 13 (PP13), pregnancy-associated plasma protein A (PAPP-A), a disintegrin and metalloprotease-12 (ADAM12), activin A, or inhibin A measured in first or early second trimester and uterine artery Doppler in second trimester appear promising (sensitivity 60%-80%, specificity >80%). In high-risk populations, the combination of PP13 and pulsatility index in first trimester showed 90% sensitivity and 90% specificity in a single study limited to severe preeclampsia.
Combinations of biochemical and ultrasonographic markers improved the performance of early prediction of preeclampsia. From a perspective of integrative medicine, large population-based studies evaluating algorithms combining multiple markers are needed, if screening approaches are to be eventually implemented.
早期识别有子痫前期风险的孕妇是实施预防措施的重点。一些生化和超声参数已显示出有希望的预测性能,但到目前为止,还没有经过临床验证的筛选程序。
我们使用一系列关键词,回顾了电子数据库(Medline、Embase,截至 2009 年 5 月的所有记录)中报告的生物和超声标记物预测子痫前期的表现,包括单一标记物和标记物组合。我们根据研究人群的妊娠年龄和风险水平对数据进行了分析。我们使用 QUADAS(诊断准确性研究的质量评估)评估了纳入研究的方法学质量。我们确定了 37 项相关研究,评估了 71 种不同的生化和超声标记物组合。大多数研究是在妊娠中期对小规模高危人群进行的,子痫前期的病例很少。与单一标记物相比,标记物组合通常会提高敏感性和/或特异性。在低危人群中,包括胎盘蛋白 13(PP13)、妊娠相关血浆蛋白 A(PAPP-A)、解整合素和金属蛋白酶 12(ADAM12)、激活素 A 或抑制素 A 在第一或妊娠早期测量和妊娠中期子宫动脉多普勒超声的组合似乎很有前途(敏感性 60%-80%,特异性>80%)。在高危人群中,在一项仅限于严重子痫前期的研究中,在妊娠早期联合使用 PP13 和搏动指数的组合表现出 90%的敏感性和 90%的特异性。
生化和超声标记物的组合提高了子痫前期早期预测的性能。从综合医学的角度来看,如果要最终实施筛查方法,需要进行评估结合多种标记物的算法的大型基于人群的研究。